Denali Therapeutics Inc. (DNLI)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Denali Therapeutics Inc. reported revenue of $0. The company ran a net loss. It held $1.14B in total assets against $131.09M in total liabilities.
Key ratios (FY2025)
-50.6%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $330.53M | $105.06M | $48.66M | $335.56M | $26.32M | $129.10M | $0 | $0 |
| Operating Income | -$555.34M | -$487.34M | -$196.70M | -$340.74M | -$295.75M | $62.72M | -$213.18M | -$46.37M | -$90.14M | -$87.43M |
| Net Income | -$512.54M | -$422.77M | -$145.22M | -$325.99M | -$290.58M | $71.14M | -$197.61M | -$36.24M | -$88.19M | -$86.65M |
| EPS (Diluted) | $-2.97 | $-2.57 | $-1.06 | $-2.60 | $-2.39 | $0.63 | $-2.07 | $-0.39 | — | — |
| Total Assets | $1.14B | $1.37B | $1.15B | $1.46B | $1.40B | $1.60B | $553.23M | $661.98M | $486.72M | — |
| Total Liabilities | $131.09M | $144.50M | $122.96M | $417.81M | $441.87M | $453.75M | $158.34M | $115.14M | $20.93M | — |
| Shareholders' Equity | $1.01B | $1.23B | $1.03B | $1.04B | $962.29M | $1.15B | $394.89M | $546.85M | $465.80M | -$94.15M |
| Cash & Equivalents | $205.33M | $174.96M | $127.11M | $218.04M | $293.48M | $507.14M | $79.45M | $77.12M | $218.38M | $39.85M |
| Operating Cash Flow | -$412.60M | -$347.69M | -$357.99M | -$244.72M | -$211.39M | $416.15M | -$151.58M | $50.12M | -$76.64M | -$71.91M |
| Capital Expenditures | $9.50M | $15.91M | $12.94M | $17.83M | $8.50M | $3.10M | $17.92M | $3.39M | $2.88M | $6.13M |
| Shares Outstanding | 156.18M | 144.22M | 138.39M | 135.97M | 122.28M | 120.53M | 96.19M | 94.66M | 87.48M | — |